Terms: = Ovarian cancer AND PIM1, PIM, 5292, ENSG00000137193, P11309 AND Treatment
5 results:
1. Resibufogenin suppresses tumor growth and inhibits glycolysis in ovarian cancer by modulating pim1.
Li Q; Jiang C; Wang Y; Wei M; Zheng H; Xu Y; Xu X; Jia F; Liu K; Sun G; Zang J; Mo P
Naunyn Schmiedebergs Arch Pharmacol; 2019 Dec; 392(12):1477-1489. PubMed ID: 31292669
[TBL] [Abstract] [Full Text] [Related]
2. XCR1 promotes cell growth and migration and is correlated with bone metastasis in non-small cell lung cancer.
Wang T; Han S; Wu Z; Han Z; Yan W; Liu T; Wei H; Song D; Zhou W; Yang X; Xiao J
Biochem Biophys Res Commun; 2015 Aug; 464(2):635-41. PubMed ID: 26166822
[TBL] [Abstract] [Full Text] [Related]
3. Kaempferol enhances the suppressive function of Treg cells by inhibiting FOXP3 phosphorylation.
Lin F; Luo X; Tsun A; Li Z; Li D; Li B
Int Immunopharmacol; 2015 Oct; 28(2):859-65. PubMed ID: 25870037
[TBL] [Abstract] [Full Text] [Related]
4. SGI-1776, an imidazo pyridazine compound, inhibits the proliferation of ovarian cancer cells by inactivating pim-1.
Xie J; Bai J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2014 Jul; 39(7):649-57. PubMed ID: 25080901
[TBL] [Abstract] [Full Text] [Related]
5. Class III β-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer.
De Donato M; Mariani M; Petrella L; Martinelli E; Zannoni GF; Vellone V; Ferrandina G; Shahabi S; Scambia G; Ferlini C
J Cell Physiol; 2012 Mar; 227(3):1034-41. PubMed ID: 21520077
[TBL] [Abstract] [Full Text] [Related]
